Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

94.7%

+8.2% vs industry average

Late-Stage Pipeline

23%

5 trials in Phase 3/4

Results Transparency

17%

3 of 18 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
12(60.0%)
Phase 3
5(25.0%)
Phase 2
2(10.0%)
N/A
1(5.0%)
20Total
Phase 1(12)
Phase 3(5)
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07340658Phase 3Not Yet Recruiting

A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT06315205Phase 1Active Not Recruiting

Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women

Role: lead

NCT07401381Phase 1Not Yet Recruiting

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Role: lead

NCT05480046Completed

Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse

Role: lead

NCT06276361Phase 1Completed

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

Role: lead

NCT03401320Phase 1Completed

Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

Role: lead

NCT01788774Phase 1Completed

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths

Role: lead

NCT03870880Phase 3Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

Role: lead

NCT03160521Phase 3Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

Role: lead

NCT05179525Phase 1Completed

Comparative Bioavailability of Risperidone.

Role: lead

NCT03527186Phase 1Completed

Comparative Bioavailability of Risperidone

Role: lead

NCT02808273Completed

Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction

Role: collaborator

NCT03363477Phase 1Completed

Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers

Role: lead

NCT02086786Phase 2Completed

Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia

Role: lead

NCT01320410Phase 1Completed

Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM®

Role: lead

NCT01264523Not ApplicableCompleted

Nutritional Intervention With Moderately High-protein, Low-glycemic Load Products in Type-2 Diabetes Patients

Role: collaborator

NCT00629733Phase 1Completed

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Role: lead

NCT00413088Phase 1Completed

Study to Assess Bemiparin Pharmacokinetics in Renal Insufficiency and in the Elderly

Role: lead

NCT00863577Phase 1Completed

Pharmacokinetic Study of Two Oral Bemiparin Formulations

Role: lead

NCT00448903Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of Sodium Bemiparin for Treatment of Diabetic Foot Ulcers

Role: lead